New cocktail aims to outsmart pancreatic cancer

NCT ID NCT05721846

Ongoing Disease control Sponsor: Inna Chen, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab), a vaccine targeting TGFβ-15, and targeted radiation for pancreatic cancer that has not responded to standard treatments. The goal is to see if this mix can safely boost the immune system's attack on tumors. Only 20 participants are enrolled, and the main focus is on side effects and signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab, ipilimumab, TGFβ-15 peptide vaccine, and stereotactic body radiotherapy
What this could lead to: If successful, this could point toward a new combination treatment that helps control pancreatic cancer when other therapies have failed.
What could go wrong: This is a very early Phase 1 trial with only 20 participants, so it is primarily testing safety. The combination may cause significant side effects and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Herlev & Gentofte University Hospital, Denmark

Herlev, 2730, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.